More than nine in ten people carry a gene variant that changes how they handle a common medication. What a clinical functional genomics panel can tell you about hormone therapy, antidepressants, and statins, what it cannot, and how Amsara uses it.
One blood draw, more than fifty cancers, and a lot of misunderstanding. The 2026 PATHFINDER 2 and NHS-Galleri results, the FDA panel this month, what a positive result really means, and how to get the test in Arizona.
Only 6.8 percent of residents feel prepared to manage menopause, and the average visit lasts fifteen minutes. What concierge menopause care means in practice, why the model exists, what it costs in Arizona, and how to tell a good version from an expensive one.
Semaglutide and tirzepatide produce 15–21% average weight loss in trials — and two-thirds of it returns within a year of stopping. An honest clinical look at who GLP-1s serve, who they don’t, and what to test first.
Hot flashes are only the beginning. A complete guide to perimenopause symptoms — vasomotor, sleep, mood, metabolic, and more — plus the lab work that explains them and rules out the look-alikes.
For most healthy women under 60 or within 10 years of menopause, current evidence says the benefits of hormone therapy outweigh the risks. Here is what the WHI got wrong, what changed at the FDA in 2025, and how to find out what is right for you.